Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
US Department of Justice
Federal Trade Commission
Boehringer Ingelheim

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,067,436

« Back to Dashboard

Title:c-Met modulators and methods of use
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s): Bannen; Lynne Canne (Pacifica, CA), Chan; Diva Sze-Ming (San Francisco, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (San Leandro, CA), Forsyth; Timothy Patrick (Hayward, CA), Huynh; Tai Phat (Oakland, CA), Jammalamadaka; Vasu (Pleasanton, CA), Khoury; Richard George (Redwood City, CA), Leahy; James William (San Leandro, CA), Mac; Morrisson B. (San Francisco, CA), Mann; Grace (Brisbane, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Takeuchi; Craig Stacy (Burlingame, CA), Wang; Yong (Forster City, CA), Xu; Wie (Danville, CA)
Assignee: Exelixis, Inc. (South San Francisco, CA)
Filing Date:May 24, 2007
Application Number:11/753,514
Claims:1. A method of treating a disease or disorder, comprising administering to a mammal in need of the treatment a therapeutically effective amount of a compound having the following structure: ##STR00548## or a pharmaceutically acceptable salt thereof, or a composition containing a) a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof; and optionally b) an excipient, wherein the disease or disorder is, ovarian cancer, prostate cancer, or lung cancer or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein the disease or disorder is lung cancer.

3. The method according to claim 1, wherein the disease or disorder is ovarian cancer.

4. The method according to claim 1, wherein the disease or disorder is prostate cancer.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.